Diopsys to Reveal the New Diopsys® NOVA-pERG Vision Test at Vision Expo East

Share Article

Diopsys will be presenting their complete Diopsys NOVA product line, including the Diopsys NOVA-VEP and the new Diopsys NOVA-pERG module, at the International Vision Expo and Conference in New York, March 15-17th.

Diopsys at Vision Expo East Booth #MS6755
In one sitting, an eye care specialist can objectively measure the function of the patient’s retina while also measuring the function of the entire vision system, from the eye to the visual cortex.

Diopsys will be joining over 2,600 ophthalmologists and optometrists for the Vision Expo East Conference at the Javits Convention Center in New York City. The program features more than 325 hours of continuing education with topics such as the diagnosis and management of diseases like glaucoma and macular degeneration. One COPE course, VEPs in Clinical Care presented by Jerome Sherman, OD, FAAO, will focus on visual evoked potential (VEP) as the single best test to objectively assess the function of the visual pathway. This course highlights VEPs in early detection of multiple sclerosis, glaucoma, and mass lesions.

Diopsys specializes in the development and marketing of patient-friendly, non-invasive vision testing equipment utilizing electrophysiological technology, including VEP. The Diopsys® NOVA-VEP Vision Testing System suite of tests uses VEP technology to objectively measure the functional responses of the entire visual pathway from the anterior segment of the eye to the visual cortex. Using VEP test results can help improve sensitivity and specificity in diagnosing visual pathway disorders, including glaucoma, when used in conjunction with other diagnostic tests.

Additionally, Diopsys plans to discuss the new Diopsys® NOVA-pERG Vision Test, an office-based pattern electroretinography (ERG) test. The pERG is an evoked potential test that objectively measures the function of the retina. Data from pERG testing may help ophthalmologists and optometrists diagnose and monitor vision disorders that affect the retina like macular degeneration and diabetic maculopathy.

One of the reasons pERG is so helpful to doctors is that it assesses the function of the retina. Most other diagnostic tests they have assess just the retina’s structure or appearance. “The Diopsys® NOVA-pERG is an important addition to the Diopsys® NOVA suite of tests. In one sitting, an eye care specialist can objectively measure the function of the patient’s retina while also measuring the function of the entire vision system, from the eye to the visual cortex,” said Dr. Alberto González, Diopsys Research Director.

Vision Expo East will help Diopsys educate eye care professionals on the clinical and financial benefits of adding electrophysiological testing to their practice.

About Diopsys
Diopsys, Inc. (http://www.diopsys.com/) is a medical instrumentation company dedicated to delivering high-quality, cost-effective preventative health care solutions. The company specializes in the development and marketing of patient-friendly, non-invasive vision testing equipment utilizing electrophysiological technology.

Diopsys has developed and markets the patented Diopsys® NOVA-VEP and Diopsys® NOVA-pERG Vision Testing Systems utilized by optometrists and ophthalmologists to help in the detection, diagnosis and treatment of vision disorders. Diopsys also provides the Enfant® Pediatric VEP Vision Testing System, a device used in testing for visual deficits, including amblyopia, in children as young as six months of age.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Don Lepone
Visit website